Health Care/Hospital

Sino Biological ProPure™ Endotoxin-Free Proteins: The "Invisible Guardian" of Biopharmaceuticals

HOUSTON, April 1, 2026 /PRNewswire/ -- After months of meticulous work, your cells suddenly behave unpredictably, or your mouse models develop fever and systemic inflammation during critical studies. The hidden culprit may be endotoxin, the lipopolysaccharide (LPS) from gram-negative bacteria. Ev...

2026-04-01 18:30 3238

Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma

SHANGHAI, March 31, 2026 /PRNewswire/ -- 31 March 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that  its independently developed, highly selective, oral small-molecule FGFR4 inhibitor irpagratinib (ABSK-011), has been granted Orphan Drug Desig...

2026-04-01 10:02 4644

Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland

* Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters * Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support * Plans further investments to add capabilities and strengthe...

2026-03-31 22:00 4873

NUH LAUNCHES INNOVATION HUB TO ACCELERATE SMART SOLUTIONS AND TRANSFORM HEALTHCARE DELIVERY

By driving a robust culture of innovation, the hub will provide a collaborative space to test and scale solutions with partners, speeding progress in patient care and operations SINGAPORE, March 31, 2026 /PRNewswire/ -- The National University Hospital (NUH) has launched the NUH Innovation Hub, ...

2026-03-31 21:31 3787

BON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives

XI'AN, China, March 31, 2026 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading provider of bio-ingredient solutions in the natural, health, and personal care industries, announced today that on February 4, 2026 it entered into a Cooperation Framework Agree...

2026-03-31 21:00 4208

Co-PSMA data published in the European Urology journal

SYDNEY, March 31, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the results fro...

2026-03-31 20:58 3900

Diagens Biotechnology Raises US$101 Million in Hong Kong IPO; Shares More Than Double on First Day of Trading

Public offering oversubscribed 1,073 times as medical imaging AI company debuts on HKEX HANGZHOU, China, March 31, 2026 /PRNewswire/ -- Hangzhou Diagens Biotechnology Co., Ltd. (HKEX: 02526) today began trading on the Main Board of The Stock Exchange of Hong Kong. Shares closed at HK$202.60, up ...

2026-03-31 18:34 5356

Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026

HONG KONG, March 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK)  ("Akeso" or the "Company") announced the results of health-related quality of life (HRQoL) data (Poster: 107P) from the HARMONi-2 study at the 2026 European Lung Cancer Congress (ELCC). The study evaluated ivonescimab, the company's...

2026-03-31 17:40 3911

Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children

SHANGHAI, March 31, 2026 /PRNewswire/ -- On 30 March, 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced thatthe U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for ABSK061, a highly selective small-...

2026-03-31 14:10 3968

NAVER D2SF Makes Follow-On Investment in Soundable Health, an AI-Driven Health Tech Startup Scaling in the U.S. Market

SEOUL, South Korea, March 30, 2026 /PRNewswire/ -- NAVER D2SF, the corporate venture capital arm of NAVER, has made a follow-on investment in Soundable Health, a health tech startup leveraging AI-powered acoustic analysis to enable clinical-grade diagnostics through everyday devices. Having parti...

2026-03-31 08:30 4607

NAVER D2SF Makes Follow-On Investment in Nuvilab, AI Nutrition Analytics Startup

SEONGNAM, South Korea, March 30, 2026 /PRNewswire/ -- NAVER D2SF, the corporate venture capital arm of NAVER, has made a follow-on investment in Nuvilab, an AI-powered nutrition analytics healthcare startup. Following its seed investment shortly after the company's founding in 2021, NAVER D2SF ha...

2026-03-31 08:30 4055

Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema

* OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab * New anatomic data demonstrates OLN324 achieves faster, greater, and more durable re...

2026-03-31 08:00 4522

Sanyou Milestone | Recognized as a "Shanghai Municipal Enterprise Technology Center," Further Validating for Innovation Excellence

SHANGHAI, March 30, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals has recently been honored as a "Shanghai Municipal Enterprise Technology Center" in recognition of its outstanding technological innovation capabilities, comprehensive R&D infrastructure, sustained investment in innovation, and r...

2026-03-30 22:00 5822

Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today a...

2026-03-30 21:53 8979

Tigermed Announces 2025 Annual Results

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annua...

2026-03-30 20:56 6366

EDAN Launches EDAN Nano OB Assist, an AI-Enabled Handheld Ultrasound, to Expand Access to Prenatal Screening in Africa

NAIROBI, Kenya, March 30, 2026 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ), a global medical device company, announced the launch of EDAN Nano OB Assist, an AI-enabled handheld ultrasound system designed to expand access to essential prenatal screening in ...

2026-03-30 20:55 3531

CELEBRATING 25 YEARS AND BEYOND OF LIFE AFTER ORGAN TRANSPLANTATION AT THE NATIONAL UNIVERSITY CENTRE FOR ORGAN TRANSPLANTATION

Honouring 35 patients who stand as inspiring examples of resilience, underscoring the long-term success of organ transplantation SINGAPORE, March 30, 2026 /PRNewswire/ -- For transplant recipients, reaching the 25-year mark is a significant achievement. According to international statistics, a d...

2026-03-30 19:43 4425

WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year

SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won"Biologics CDMO of the Year" (Large CDMOs) in the 2026 CDMO Leadership Awards. The company has also been...

2026-03-30 13:33 6188

AROA Biosurgery Completes Randomised Controlled Trial for Symphony™; Preliminary Read-Out indicates Primary Endpoint Met

AUCKLAND, New Zealand, March 29, 2026 /PRNewswire/ -- Aroa Biosurgery Limited today announced completion of its randomised controlled trial (RCT) evaluating Symphony, with a preliminary study read-out indicating the trial achieved its primary endpoint. Symphony is AROA's Cellular, Acellular and ...

2026-03-30 09:59 5237

Insilico Medicine Announces Global R&D Collaboration with Lilly

AI-driven collaboration includes an exclusive worldwide license for a portfolio of programs spanning multiple therapeutic areas. CAMBRIDGE, Mass., March 29, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial in...

2026-03-30 08:30 5391
1 ... 9101112131415 ... 317